

Item 8.01. Other Events.

On October 16, 2017, TG Therapeutics, Inc. issued the following press releases: (i) a press release providing an update on an FDA meeting for the GENUINE Phase 3 trial; (ii) a press release announcing the completion of full enrollment in the UNITY-CLL Phase 3 trial; and (iii) a press release recapping clinical data presentations at the upcoming 7th Joint ECTRIMS-ACTRIMS Meeting (collectively, the “Press Releases”). Copies of the Press Releases are being filed as Exhibits 99.1, 99.2 and 99.3 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated October 16, 2017.

99.2 Press Release, dated October 16, 2017.

99.3 Press Release, dated October 16, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.
(Registrant)

Date: October 17, 2017

By: /s/ Sean A. Power
Sean A. Power
Chief Financial Officer

INDEX TO EXHIBITS

| Exhibit Number | Description |
|-------------------|--|
| <u>99.1</u> | Press Release, dated October 16, 2017. |
| <u>99.2</u> | Press Release, dated October 16, 2017. |
| <u>99.3</u> | Press Release, dated October 16, 2017. |